For evaluating and optimization of photodynamic therapy (PDT) efficacy, there is a strong need for imaging modalities that can provide (bio)markers fast, frequently and non-invasively. By combining multiple techniques, optical imaging can simultaneously quantify several PDT-response biomarkers including blood flow, oxygenation and photosensitizer (PS) fluorescence concentration during PDT. Additionally, fluorescence imaging can provide high contrast for visualization for PDT planning and dose optimization. I will present monitoring and predicting the PDT response of oral cancer at both preclinical and clinical settings. The results indicate that real-time blood flow measurements can provide useful feedback for PDT optimization in preclinical models, and that multi-parameter analysis of blood flow, PS fluorescence concentration and oxygen saturation can predict the response of oral cancer patients at the operating room. In the final part of the talk, I will present a novel, dual-channel, dual-modal theranostic endoscope that allows imaging, therapeutic light delivery, and light-triggered release of doxorubicin (Dox) from liposomes to optimize chemophotoherapy, the combination of PDT and chemo. The feasibility of noninvasive, continuous monitoring and optimization based on quantitative Dox/PS concentration distributions will be presented in an ovarian cancer model.
|